title: Fibroblast growth factor 2 orchestrates angiogenic networking in non-GIST STS patients.
abstract: BACKGROUND
  Non-gastrointestinal stromal tumor soft-tissue sarcomas (non-GIST STSs) constitute a heterogeneous group of tumors with poor prognosis. Fibroblast growth factor 2 (FGF2) and fibroblast growth factor receptor-1 (FGFR-1), in close interplay with platelet-derived growth factor-B (PDGF-B) and vascular endothelial growth factor receptor-3 (VEGFR-3), are strongly involved in angiogenesis. This study investigates the prognostic impact of FGF2 and FGFR-1 and explores the impact of their co-expression with PDGF-B and VEGFR-3 in widely resected tumors from non-GIST STS patients.
  
  
  METHODS
  Tumor samples from 108 non-GIST STS patients were obtained and tissue microarrays were constructed for each specimen. Immunohistochemistry was used to evaluate the expressions of FGF-2, FGFR-1, PDGF-B and VEGFR-3.
  
  
  RESULTS
  In the multivariate analysis, high expression of FGF2 (P = 0.024, HR = 2.2, 95% CI 1.1-4.4) and the co-expressions of FGF2 & PDGF-B (overall; P = 0.007, intermediate; P = 0.013, HR = 3.6, 95% CI = 1.3-9.7, high; P = 0.002, HR = 6.0, 95% CI = 2.0-18.1) and FGF2 & VEGFR-3 (overall; P = 0.050, intermediate; P = 0.058, HR = 2.0, 95% CI = 0.98-4.1, high; P = 0.028, HR = 2.6, 95% CI = 1.1-6.0) were significant independent prognostic indicators of poor disease-specific survival.
  
  
  CONCLUSIONS
  FGF2, alone or in co-expression with PDGF-B and VEGFR-3, is a significant independent negative prognosticator in widely resected non-GIST STS patients.
authors: Institute of Medical Biology, University of Tromso, PB 9037, Tromso, Norway. Kilvaer@gmail.com
authors: Thomas K
authors: TK
authors: Kilvaer
authors: Andrej
authors: A
authors: Valkov
authors: Sveinung W
authors: SW
authors: Sorbye
authors: Eivind
authors: E
authors: Smeland
authors: Roy M
authors: RM
authors: Bremnes
authors: Lill-Tove
authors: LT
authors: Busund
authors: Tom
authors: T
authors: Donnem
mesh_terms: D000328:Adult; D002465:Cell Movement; D018572:Disease-Free Survival; D005260:Female; D016222:Fibroblast Growth Factor 2 / Q000378:metabolism*; D046152:Gastrointestinal Stromal Tumors / Q000098:blood supply* / Q000453:epidemiology / Q000378:metabolism* / Q000473:pathology; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009389:Neovascularization, Pathologic / Q000378:metabolism*; D015588:Observer Variation; D016016:Proportional Hazards Models; D020574:Proto-Oncogene Proteins c-sis / Q000378:metabolism; D051496:Receptor, Fibroblast Growth Factor, Type 1 / Q000378:metabolism; D012509:Sarcoma / Q000098:blood supply* / Q000453:epidemiology / Q000378:metabolism* / Q000473:pathology; D046888:Tissue Array Analysis; D040321:Vascular Endothelial Growth Factor Receptor-3 / Q000378:metabolism; D055815:Young Adult
chemical_list: D020574:Proto-Oncogene Proteins c-sis; D016222:Fibroblast Growth Factor 2; D051496:Receptor, Fibroblast Growth Factor, Type 1; D040321:Vascular Endothelial Growth Factor Receptor-3